IRLAB Therapeutics

Dementia
#CNS #IRLAB Therapeutics #Neurodegenerative disorders #Parkinson's #Phase I trial

Drug candidate for apathy enters Phase I trials

Swedish company IRLAB Therapeutics has initiated a Phase I study of IRL757, its drug candidate for apathy – a condition associated with Parkinson’s disease and other CNS diseases. IRL757 has shown positive effects in several preclinical models of cognitive function, including improved motivation. This… Read More

#News

Parkinson's disease
#Charity #Funding #IRLAB Therapeutics #Parkinson's #The Michael J Fox Foundation

Parkinson’s charity awards $2m to support apathy treatment

Swedish company IRLAB Therapeutics has been awarded funding of over $2 million from The Michael J Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to conduct a Phase I clinical study of IRL757, a drug candidate in development as a novel treatment of… Read More

#News